Yahoo Insider Transactions
ValueWalk - Breaking News or Link is on Stocktwits and The Fly On The Wall
great entry - thanks all
Buoyed by 6-week hep C data, Achillion sets out to test even faster cure
February 9, 2015 | By John Carroll
Now researchers are using the data to set the stage to see if the results can be replicated even faster in a 4-week trial. Competing drugs from Gilead and AbbVie have forced out earlier standard remedies with oral combos that are much easier to tolerate and much more likely to provide a lasting cure. The goal now is to find ways to do it quicker and with less expense, providing an opening for some of the companies still in the hunt.
"The ability to further shorten treatment duration to only six weeks and maintain excellent SVR12 rates remains the goal for clinicians and patients, and I am pleased that these Phase 2 results support that goal. The profile of ACH-3102, represents an important and exciting treatment option to shorten treatment durtion for patients infected with HCV," commented Professor Edward Gane, the lead investigator in the study.
have good weekend
The Fly On The Wall
Breaking News Feed
H.C. Wainwright Initiates Buy on Celladon ( CLDN ) - Cites Impressive Trial Results For Heart Failure Therapy
Clinical trial results are impressive—demonstrating statistically significantly improved outcomes. MYDICAR has been granted Breakthrough Therapy Designation,We see MYDICAR as a transformational approach to treating systolic heart failure."
Adam Feuerstein @adamfeuerstein ·
$RGLS — Sorry to break bad news to @RNAiAnalyst but single dose of RG-101 is an inferior HepC therapy.
From Anderson Cancer Center Up to Five CARs Are Now Excepted To Enter The Clinic in 2015
Advaxis has entered into a clinical trial collaboration agreement with Incyte (INCY) to evaluate the combination of ADXS-HPV, with Incyte's epacadostat (ADXS)